Well, one reason is that they are including confirmed deaths, provisional deaths, and presumed deaths for COVID, in the death count for the US. But, in the UK, they only post the confirmed deaths for COVID.

Confirmed deaths for COVID are about half their total deaths.

Doctors are also calling non-COVID deaths as COVID deaths.

Because, Medicare pays hospitals more for COVID deaths.

There are virtually no flu deaths in the US anymore. That’s BS. They just count flu deaths and pneumonia deaths as COVID deaths.

If 200,000 people have died of COVID in the US, that’s 0.06% of the population. It was a very bad flu season.

0.05% of the US population died in the H1N3 flu epidemic during the 1968-69 flu season.

But, the H1N3 virus keeps coming around again and again, but we don’t add it all up. For COVID, we just keep adding deaths without separating it out by year.

For instance, 360,000 people died of the flu in the last 10 years, but we separate it out by year. Not COVID. It’s just a running total.

At least two Pandemic vaccines include a virus that injects DNA copies of Pandemic virus RNA into human genes. Viruses that are used this way are called vectors. The adenovirus is often used as a vector in vaccines. Nobody knows the long term effects of having pandemic virus DNA inserted into our genes, because the data is not in yet.

Virus vectors

These vaccines use a virus, often weakened and incapable of causing disease itself, to deliver a virus antigen into the body. The virus’ ability to infect cells, express large amount of antigen and in turn trigger a strong immune response make these vaccines promising.

Examples of viruses used as vectors include vaccinia virus (used in the first ever vaccine, against smallpox) and adenovirus (a common cold virus).

Pros

highly specific delivery of antigens to target cells and high expression of antigen after vaccination
often a single dose is enough to stimulate long-term protection.

Cons

People may have existing levels of immune protection to the virus vector, reducing the effectiveness of the vaccine. In other words, the body raises an immune response to the vector rather than to the antigen.

Low-scale production of some virus-vectored vaccines means they are less cost-effective.

One high-profile example is the University of Oxford/AstraZeneca vaccine AZD1222 (formerly known as ChAdOx1), one of the two vaccines the Australian government wishes to use should phase 3 clinical trials prove successful. This vaccine is based on a modified chimpanzee adenovirus.

Two adenovirus based COVID-19 vaccines have been approved for early or limited use internationally. These were developed by the Chinese Academy of Military Medical Sciences with CanSino Biologics and the Gamaleya Research Institute, part of Russia’s health ministry.